Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonas Bergh

Showing results (1-10 of 294) with videos related to

Pageof 30
Sort By:
Lakartidningen|April 29, 2015
[Sweden does not prioritize important cancer drugs]Jonas Bergh
Lancet (London, England)|July 30, 2003
Breast-cancer prevention: is the risk-benefit ratio in favour of tamoxifen?Jonas Bergh
Breast (Edinburgh, Scotland)|December 9, 2003
Best use of adjuvant systemic therapies II, chemotherapy aspects: dose of chemotherapy-cytotoxicity, duration and responsivenessJonas Bergh
Lakartidningen|January 3, 2018
Jonas Bergh
Breast (Edinburgh, Scotland)|October 26, 2005
Adjuvant chemotherapy for breast cancer--"one fits all"?Jonas Bergh
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Quo vadis with targeted drugs in the 21st century?Jonas Bergh
Acta Oncologica (Stockholm, Sweden)|April 8, 2004
Weekly taxanes--a leap forward or a minute progress?Barbro Linderholm, Jonas Bergh
BMC Cancer|July 23, 2011
A simple method for assigning genomic grade to individual breast tumoursKristian Wennmalm, Jonas Bergh
Nature Reviews. Clinical Oncology|February 22, 2012
Hurdles in anticancer drug development from a regulatory perspectiveBertil Jonsson, Jonas Bergh
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2010
Insights into the place of fulvestrant for the treatment of advanced endocrine responsive breast cancerAnthony Howell, Jonas Bergh
Pageof 30

Showing results (1-10 of 294) with videos related to

Sort By:
Pageof 30
Lakartidningen|April 29, 2015
[Sweden does not prioritize important cancer drugs]Jonas Bergh
Lancet (London, England)|July 30, 2003
Breast-cancer prevention: is the risk-benefit ratio in favour of tamoxifen?Jonas Bergh
Breast (Edinburgh, Scotland)|December 9, 2003
Best use of adjuvant systemic therapies II, chemotherapy aspects: dose of chemotherapy-cytotoxicity, duration and responsivenessJonas Bergh
Lakartidningen|January 3, 2018
Jonas Bergh
Breast (Edinburgh, Scotland)|October 26, 2005
Adjuvant chemotherapy for breast cancer--"one fits all"?Jonas Bergh
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Quo vadis with targeted drugs in the 21st century?Jonas Bergh
Acta Oncologica (Stockholm, Sweden)|April 8, 2004
Weekly taxanes--a leap forward or a minute progress?Barbro Linderholm, Jonas Bergh
BMC Cancer|July 23, 2011
A simple method for assigning genomic grade to individual breast tumoursKristian Wennmalm, Jonas Bergh
Nature Reviews. Clinical Oncology|February 22, 2012
Hurdles in anticancer drug development from a regulatory perspectiveBertil Jonsson, Jonas Bergh
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2010
Insights into the place of fulvestrant for the treatment of advanced endocrine responsive breast cancerAnthony Howell, Jonas Bergh
Pageof 30